Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Clin Cancer Res. 2013 Mar 13;19(9):2342–2354. doi: 10.1158/1078-0432.CCR-12-2623

Figure 5.

Figure 5

LY294002 attenuates development of cancer in IL-10−/− mice treated with Piroxicam. Graphical representation of the frequencies of (A) invasive lesions, (B) % BRDU+, (C) %TUNEL+, (D) %pAkt+ epithelial and (E) %pAkt+ stromal cells per total nuclei in the colon of untreated and LY294002 treated Il-10−/− mice. (F) Histological evaluation of IL-10−/− and IL-10−/− mice treated with LY294002. H & E staining at 100X & 200X magnification of IL-10−/− mice 56 days post Piroxicam ± LY294002 treatment; arrow indicates invaded colonic crypts. (G) BrdU staining on colon of IL-10−/− or IL-10−/− mice treated with LY294002 (H) TUNEL staining on colon of IL-10−/− or IL-10−/− treated with LY294002 (I) pAkt staining in colonic mucosal epithelium of IL-10−/− or IL-10−/− mice treated with LY294002. (J) pAKT staining in colonic stroma of IL-10−/− or IL-10−/− mice treated with LY294002, arrows indicate pAKT+ cells. Scale bar = 50 µm, * P < 0.05 represents the result of Student t test.

HHS Vulnerability Disclosure